Aktien Sensor

Bayer AG is facing significant financial challenges due to ongoing Roundup litigation, with a recent verdict ordering the company to pay a substantial sum and impacting its stock price.

A US jury has ruled in favor of a plaintiff who claims Bayer’s Roundup herbicide caused his cancer, potentially setting a precedent for billions of dollars in damages.

Bayer AG expects a decline in operating profit for 2025, with net sales remaining roughly flat, in line with market expectations.

Bayer’s stock price has experienced fluctuations, but remains relatively stable, while its pharmaceutical division shows promise with the approval of Finerenon in over 90 countries.

Bayer’s stock price has surged 1.5% as the company prepares to sell a 4.5 million euro art collection, potentially generating significant revenue for future growth and innovation.

Bayer’s heart medication Acoramidis has received EU approval, potentially boosting the company’s revenue and market share, but its success is uncertain and may not be enough to revive its dwindling fortunes.